TimesSquare Capital Management LLC Sells 24,060 Shares of Xenon Pharmaceuticals Inc. $XENE

TimesSquare Capital Management LLC trimmed its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 4.3% during the 4th quarter, Holdings Channel reports. The firm owned 532,740 shares of the biopharmaceutical company’s stock after selling 24,060 shares during the period. TimesSquare Capital Management LLC’s holdings in Xenon Pharmaceuticals were worth $23,877,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of XENE. Danske Bank A S bought a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter valued at $32,000. Blue Trust Inc. raised its position in shares of Xenon Pharmaceuticals by 2,560.7% during the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 717 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter valued at $39,000. Osaic Holdings Inc. raised its position in shares of Xenon Pharmaceuticals by 541.4% during the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,034 shares during the period. Finally, State of Wyoming raised its position in shares of Xenon Pharmaceuticals by 112.8% during the 3rd quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 610 shares during the period. 95.45% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, insider Andrea Difabio sold 2,607 shares of Xenon Pharmaceuticals stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total value of $156,706.77. Following the completion of the transaction, the insider directly owned 4,893 shares of the company’s stock, valued at $294,118.23. This trade represents a 34.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Ian Mortimer sold 270,000 shares of Xenon Pharmaceuticals stock in a transaction on Monday, March 9th. The stock was sold at an average price of $60.33, for a total transaction of $16,289,100.00. Following the completion of the transaction, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at $361,980. The trade was a 97.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 296,707 shares of company stock valued at $17,845,365 in the last three months. Corporate insiders own 4.07% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on XENE shares. Guggenheim reaffirmed a “buy” rating and set a $90.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. JPMorgan Chase & Co. raised their target price on shares of Xenon Pharmaceuticals from $77.00 to $80.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Xenon Pharmaceuticals from $56.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Royal Bank Of Canada raised their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Finally, Wedbush cut their target price on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a research note on Monday, March 16th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $77.07.

Xenon Pharmaceuticals Stock Performance

XENE opened at $54.05 on Wednesday. The stock has a market capitalization of $5.23 billion, a price-to-earnings ratio of -11.50 and a beta of 0.65. The company has a fifty day moving average of $56.54 and a 200 day moving average of $47.35. Xenon Pharmaceuticals Inc. has a fifty-two week low of $28.19 and a fifty-two week high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, meeting the consensus estimate of ($1.17). During the same quarter in the previous year, the firm earned ($0.83) EPS. On average, equities research analysts forecast that Xenon Pharmaceuticals Inc. will post -4.88 earnings per share for the current year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.